Statistik Asas
| LEI | Y6ZDD9FP4P8JSSJMW954 |
| CIK | 885725 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Boston Scientific Corporation
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 29, 2025 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commis |
|
| August 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 1-11083 BOSTON SCIENTIFIC CORPORATION (Exact name o |
|
| August 1, 2025 |
Subsidiary Issuer of Guaranteed Securities. EXHIBIT 22 Subsidiary Issuer of Guaranteed Securities Boston Scientific (the “Registrant”) is the guarantor of the senior unsecured registered notes listed below issued by American Medical Systems Europe B. |
|
| August 1, 2025 |
EXHIBIT 10.3 2025 Boston Scientific Annual Bonus Plan Performance Period January 1 - December 31 Version: April 2025 I.Establishment and Purpose of the Plan Boston Scientific Corporation has established the Boston Scientific Corporation Annual Bonus Plan ("Plan"). As explained in detail below, the Plan basically works as follows. For each Performance Year, there is a Target Bonus Pool, which is th |
|
| August 1, 2025 |
Form of EC Non-CEO Change in Control Agreement. # EXHIBIT 10.2 [FORM OF EC NON-CEO CHANGE IN CONTROL AGREEMENT] [INSERT NAME] [INSERT ADDRESS] Re: Change in Control Agreement Dear [INSERT FIRST NAME]: Boston Scientific Corporation (the “Company”) considers it essential and in the best interests of its stockholders to foster the continuous employment of key management personnel. Further, the Board of Directors of the Company (the “Board”) recogniz |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 23, 2025 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I. |
|
| July 23, 2025 |
Boston Scientific announces results for second quarter 2025 FOR IMMEDIATE RELEASE Boston Scientific announces results for second quarter 2025 Marlborough, Mass. |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One): þ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 28, 2025 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commissio |
|
| May 22, 2025 |
Exhibit 1.01 — Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. Exhibit 1.01 Conflict Minerals Report of Boston Scientific Corporation For the Year Ended December 31, 2024 This Conflict Minerals Report (this “Report”) of Boston Scientific Corporation for the year ended December 31, 2024 is filed in accordance with the rules under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Rule 13p-1 under the Exchange Act (“Rule 13p-1”) imposes certa |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM SD Specialized Disclosure Report BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) DELAWARE 1-11083 04-2695240 (State or other (Commission (IRS employer jurisdiction of file number) identification no. |
|
| May 6, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 1, 2025 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commission |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 1-11083 BOSTON SCIENTIFIC CORPORATION (Exact name |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 18, 2025 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commiss |
|
| April 23, 2025 |
Form of Offer Letter dated April 18, 2025 between Mr. Monson and Boston Scientific Corporation. April 18, 2025 Jonathan Monson Dear Jon: Congratulations on your promotion to Boston Scientific’s Executive Committee, effective June 30, 2025. |
|
| April 23, 2025 |
Boston Scientific Chief Financial Officer (CFO) Dan Brennan to retire; Jon Monson, senior vice president, Investor Relations to succeed Brennan MARLBOROUGH, Mass. |
|
| April 23, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 23, 2025 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I. |
|
| April 23, 2025 |
Boston Scientific announces results for first quarter 2025 FOR IMMEDIATE RELEASE Boston Scientific announces results for first quarter 2025 Marlborough, Mass. |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| February 26, 2025 |
Boston Scientific announces completion of €1.5 billion offering of senior notes Exhibit 99.2 Boston Scientific announces completion of €1.5 billion offering of senior notes MARLBOROUGH, Mass., February 26, 2025 – Boston Scientific Corporation (the “Company”) (NYSE: BSX) today announced that American Medical Systems Europe B.V. (“AMS Europe”), its wholly owned finance subsidiary, has completed a public offering of €850,000,000 aggregate principal amount of 3.000% notes due 203 |
|
| February 26, 2025 |
Form of 3.250% Senior Note due 2034. Exhibit 4.3 THIS GLOBAL SECURITY IS REGISTERED IN THE NAME OF THE ENTITY APPOINTED AS COMMON DEPOSITARY (AS DEFINED IN THE INDENTURE) OR A NOMINEE OF THE COMMON DEPOSITARY. THIS GLOBAL SECURITY IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE COMMON DEPOSITARY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND NO TRANSFER OF THIS |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 21, 2025 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Comm |
|
| February 26, 2025 |
February 21, 2025, among American Medical Systems Europe B.V., Boston Scientific Corporation and the Exhibit 1.1 Execution Version AMERICAN MEDICAL SYSTEMS EUROPE B.V., as Issuer Debt Securities Fully and Unconditionally Guaranteed by BOSTON SCIENTIFIC CORPORATION UNDERWRITING AGREEMENT-BASIC PROVISIONS February 21, 2025 To: The Underwriters named in the within-mentioned Terms Agreement Ladies and Gentlemen: American Medical Systems Europe B.V. (the “Issuer”), incorporated as a private company wi |
|
| February 26, 2025 |
Form of 3.000% Senior Note due 2031. Exhibit 4.2 THIS GLOBAL SECURITY IS REGISTERED IN THE NAME OF THE ENTITY APPOINTED AS COMMON DEPOSITARY (AS DEFINED IN THE INDENTURE) OR A NOMINEE OF THE COMMON DEPOSITARY. THIS GLOBAL SECURITY IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE COMMON DEPOSITARY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND NO TRANSFER OF THIS |
|
| February 26, 2025 |
Boston Scientific announces pricing of €1.5 billion of senior notes Exhibit 99.1 Boston Scientific announces pricing of €1.5 billion of senior notes MARLBOROUGH, Mass., February 21, 2025 – Boston Scientific Corporation (the “Company”) (NYSE: BSX) today announced that American Medical Systems Europe B.V. (“AMS Europe”), its wholly owned finance subsidiary, has priced a public offering of €850,000,000 aggregate principal amount of 3.000% notes due 2031 and €650,000, |
|
| February 24, 2025 |
Table 1: Newly Registered and Carry Forward Securities Calculation of Filing Fee Tables S-3 BOSTON SCIENTIFIC CORP Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Debt 3. |
|
| February 24, 2025 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(2) Registration No. 333-285032 PROSPECTUS SUPPLEMENT (To Prospectus dated February 18, 2025) €1,500,000,000 American Medical Systems Europe B.V. (incorporated as a private company with limited liability in the Netherlands with its statutory seat in Amsterdam, the Netherlands) €850,000,000 3.000% Senior Notes due 2031 €650,000,000 3.250% Senior Note |
|
| February 21, 2025 |
SUBJECT TO COMPLETION, DATED FEBRUARY 21, 2025 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| February 21, 2025 |
Filed Pursuant to Rule 433 under the Securities Act of 1933 Registration Statement No. |
|
| February 18, 2025 |
Exhibit 10.56 2024 Boston Scientific Annual Bonus Plan Performance Period January 1 - December 31 Version: Final 2024 I.Establishment and Purpose of the Plan Boston Scientific Corporation has established the Boston Scientific Corporation Annual Bonus Plan ("Plan"). As explained in detail below, the Plan basically works as follows. For each Performance Year, there is a Target Bonus Pool, which is t |
|
| February 18, 2025 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K of which this exhibit is a part, Boston Scientific Corporation (the “Company”) has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): (1) our commo |
|
| February 18, 2025 |
As filed with the Securities and Exchange Commission on February 18, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on February 18, 2025 Registration No. |
|
| February 18, 2025 |
Calculation of Filing Fee Tables S-3 BOSTON SCIENTIFIC CORP Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Debt Senior Debt Securities 457(r) 0. |
|
| February 18, 2025 |
List of Boston Scientific's subsidiaries as of January 31, 2025. EXHIBIT 21 List of worldwide subsidiaries of Boston Scientific Corporation as of January 31, 2025 Structure of ownership and control: Boston Scientific wholly owns or has a majority interest in all of the below mentioned entities. |
|
| February 18, 2025 |
Exhibit 4.1 BOSTON SCIENTIFIC CORPORATION American Medical Systems Europe B.V. [ ] as Issuer or Guarantor, as applicable, for each series of Securities from time to time AND U.S. Bank Trust Company, National Association, as Trustee Form of Indenture Dated as of [ ], 20[ ] DEBT SECURITIES BOSTON SCIENTIFIC CORPORATION American Medical Systems Europe B.V. Reconciliation and tie between Trust Indentu |
|
| February 18, 2025 |
Exhibit 10.20 THE BOSTON SCIENTIFIC CORPORATION EXECUTIVE RETIREMENT PLAN As Amended and Restated Effective March 1, 2025 Section 1—Nature and Purpose Boston Scientific Corporation maintains the Boston Scientific Corporation Executive Retirement Plan, which is an unfunded, nonqualified deferred compensation plan for a select group of management and highly compensated employees. The Plan is intende |
|
| February 18, 2025 |
Exhibit 10.63 BOSTON SCIENTIFIC CORPORATION RESTRICTED STOCK AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORS This Agreement, dated as of the %%OPTIONDATE,'Month DD, YYYY%-% (the “Grant Date”), is between Boston Scientific Corporation, a Delaware corporation (the “Company”), and the person whose name appears on the Signature Page of this Agreement (the “Participant”), a non-employee director of the Comp |
|
| February 18, 2025 |
Amended and Restated 2011 Long-Term Incentive Plan of the Company, as amended January 1, 2025.# Exhibit 10.32 BOSTON SCIENTIFIC CORPORATION AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN (As Amended January 1, 2025) 1.ADMINISTRATION a.Administrator Authority. Subject to the express provisions of the Plan and except to the extent prohibited by Applicable Laws, the Administrator has the authority to (i) interpret the Plan; determine eligibility for and grant Awards and designate the Partic |
|
| February 18, 2025 |
Exhibit 25.1 securities and exchange commission Washington, D.C. 20549 FORM T-1 Statement of Eligibility Under The Trust Indenture Act of 1939 of a Corporation Designated to Act as Trustee Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) ¨ U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 I.R.S. E |
|
| February 18, 2025 |
Exhibit 10.64 BOSTON SCIENTIFIC CORPORATION RESTRICTED STOCK UNIT AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORS This Agreement, dated as of the %%OPTIONDATE,'Month DD, YYYY'%-% (the “Grant Date”), is between Boston Scientific Corporation, a Delaware corporation (the “Company”), and the person whose name appears on the Signature Page of this Agreement (the “Participant”), a non-employee director of th |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934, or For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 1-11083 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as speci |
|
| February 18, 2025 |
Boston Scientific Corporation Stock Trading Policy Exhibit 19 Boston Scientific Corporation Stock Trading Policy Purpose The purposes of this Stock Trading Policy (this “Policy”) are: (1) to prevent insider trading by persons subject to this Policy in violation of the securities laws of the United States; (2) to prevent the possible appearance of impropriety in connection with trading or other related activities; and (3) to reduce the risk that persons subject to this Policy might be found to have engaged in activities that are otherwise inconsistent with Boston Scientific Corporation’s (“BSC” or the “Company”) Code of Conduct or standards of business ethics. |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 9, 2025 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commi |
|
| February 5, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 5, 2025 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I. |
|
| February 5, 2025 |
Boston Scientific announces results for fourth quarter and full year 2024 FOR IMMEDIATE RELEASE Boston Scientific announces results for fourth quarter and full year 2024 Marlborough, Mass. |
|
| January 16, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 16, 2025 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commi |
|
| January 16, 2025 |
UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS DIANE NACHBAUR, Derivatively on Behalf of Nominal Defendant BOSTON SCIENTIFIC CORPORATION, Plaintiff, v. |
|
| January 16, 2025 |
UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS Exhibit 99.2 UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS DIANE NACHBAUR, Derivatively on Behalf of Nominal Defendant BOSTON SCIENTIFIC CORPORATION, Plaintiff, v. MICHAEL F. MAHONEY, NELDA J. CONNORS, CHARLES J. DOCKENDORFF, YOSHIAKI FUJIMORI, DONNA A. JAMES, EDWARD J. LUDWIG, DAVID ROUX, JOHN E. SUNUNU, ELLEN M. ZANE JOSEPH M. FITZGERALD, AND DANIEL J. BRENNAN, SHAWN MCCARTHY, IAN MERED |
|
| November 22, 2024 |
Boston Scientific Corporation 2025 Organic Net Sales Growth Performance Share Program Exhibit 10.3 Boston Scientific Corporation (“Boston Scientific”) Organic Net Sales Growth Performance Share Program (“ONSG Program”) Performance Period January 1, 2025 - December 31, 2027 1.Purpose of the ONSG Program The purpose of the ONSG Program is to align Boston Scientific’s executive compensation program with the interests of shareholders and to reinforce the concept of pay for performance |
|
| November 22, 2024 |
Boston Scientific Corporation 2025 Annual Bonus Plan, effective as of January 1, 2025 Exhibit 10.1 2025 Boston Scientific Annual Bonus Plan Performance Period January 1 - December 31 Version: November 2024 1.Establishment and Purpose of the Plan Boston Scientific Corporation has established the Boston Scientific Corporation Annual Bonus Plan ("Plan"). As explained in detail below, the Plan basically works as follows. For each Performance Year, there is a Target Bonus Pool, which is |
|
| November 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 19, 2024 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Comm |
|
| November 22, 2024 |
Boston Scientific Corporation 2025 Relative Total Shareholder Return Performance Share Program Exhibit 10.2 Boston Scientific Corporation (“Boston Scientific”) Relative Total Shareholder Return Performance Share Program (“rTSR Program”) Performance Period January 1, 2025 - December 31, 2027 1.Performance Share Units The purpose of the rTSR Program is to align Boston Scientific’s executive compensation program with the interests of shareholders and to reinforce the concept of pay for perform |
|
| November 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 15, 2024 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Comm |
|
| November 15, 2024 |
Boston Scientific Closes Acquisition of Axonics, Inc. Exhibit 99.1 Boston Scientific Closes Acquisition of Axonics, Inc. MARLBOROUGH, Mass., November 15, 2024 – Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction. “Over the last decade, it has |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2024 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commi |
|
| November 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 1-11083 BOSTON SCIENTIFIC CORPORATION (Exact n |
|
| October 23, 2024 |
Boston Scientific Announces Results for Third Quarter 2024 Boston Scientific Announces Results for Third Quarter 2024 Marlborough, Mass. (October 23, 2024) - Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net |
|
| October 23, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 23, 2024 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I. |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 1-11083 BOSTON SCIENTIFIC CORPORATION (Exact name o |
|
| August 1, 2024 |
Exhibit 10.1 Execution Version THIRD AMENDMENT THIRD AMENDMENT, dated as of May 10, 2024 (this “Amendment”), to the Credit Agreement, dated as of May 10, 2021 (as amended by that certain Amendment dated as of December 21, 2022 and the Second Amendment, dated as of March 1, 2023, and as further amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), among (i) BOSTON |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 30, 2024 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commissi |
|
| July 30, 2024 |
Boston Scientific Elects David Habiger to Board of Directors Exhibit 99.1 Boston Scientific Elects David Habiger to Board of Directors MARLBOROUGH, Mass., (July 30, 2024) – Boston Scientific Corporation (NYSE: BSX) announced today the election of David Habiger to its board of directors, effective immediately. Habiger has more than 30 years of business leadership experience and currently serves as president and chief executive officer of J.D. Power. Prior to |
|
| July 24, 2024 |
Boston Scientific Announces Results for Second Quarter 2024 Boston Scientific Announces Results for Second Quarter 2024 Marlborough, Mass. (July 24, 2024) - Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent on a reported basis, 16.1 percent on an operational1 basis and 14.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net |
|
| July 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 24, 2024 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I. |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One): þ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION |
|
| May 23, 2024 |
Exhibit 1.01 — Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. Exhibit 1.01 Conflict Minerals Report of Boston Scientific Corporation For the Year Ended December 31, 2023 This Conflict Minerals Report (this “Report”) of Boston Scientific Corporation for the year ended December 31, 2023 is filed in accordance with the rules under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Rule 13p-1 under the Exchange Act (“Rule 13p-1”) imposes certa |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM SD Specialized Disclosure Report BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) DELAWARE 1-11083 04-2695240 (State or other (Commission (IRS employer jurisdiction of file number) identification no. |
|
| May 10, 2024 |
Exhibit 10.1 Execution Version THIRD AMENDMENT THIRD AMENDMENT, dated as of May 10, 2024 (this “Amendment”), to the Credit Agreement, dated as of May 10, 2021 (as amended by that certain Amendment dated as of December 21, 2022 and the Second Amendment, dated as of March 1, 2023, and as further amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), among (i) BOSTON |
|
| May 10, 2024 |
Amended and Restated By-Laws of Boston Scientific Corporation Exhibit 3.1 AMENDED AND RESTATED BY-LAWS OF BOSTON SCIENTIFIC CORPORATION A Delaware Corporation (effective as of May 9, 2024) ARTICLE I OFFICES Section 1. Registered Office. The registered office of Boston Scientific Corporation (hereafter “the corporation”) in the State of Delaware shall be as set forth in the certificate of incorporation of the corporation (as amended and/or restated from time |
|
| May 10, 2024 |
Amended and Restated By-Laws of Boston Scientific Corporation (marked to show amendments) Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF BOSTON SCIENTIFIC CORPORATION A Delaware Corporation (effective as of May 9, 2024) ARTICLE I OFFICES Section 1. Registered Office. The registered office of Boston Scientific Corporation (hereafter “the corporation”) in the State of Delaware shall be at 2711 Centerville Road, Suite 400, Wilmington, Delaware 19808. The name of the corporation’s registered |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2024 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commission |
|
| May 10, 2024 |
Boston Scientific Elects Dr. Cheryl Pegus to Board of Directors Exhibit 99.1 Boston Scientific Elects Dr. Cheryl Pegus to Board of Directors MARLBOROUGH, Mass., (May 8, 2024) – Boston Scientific Corporation (NYSE: BSX) announced today the election of Dr. Cheryl Pegus to its board of directors, effective immediately. Dr. Pegus has more than 25 years of clinical and business leadership experience, most recently serving as a partner at Morgan Health focused on im |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 2, 2024 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commission |
|
| May 6, 2024 |
Amended and Restated By-Laws of Boston Scientific Corporation Exhibit 3.1 AMENDED AND RESTATED BY-LAWS OF BOSTON SCIENTIFIC CORPORATION A Delaware Corporation ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be at 2711 Centerville Road, Suite 400, Wilmington, Delaware 19808. The name of the corporation’s registered agent at such address shall be Corporation Service Company. Section 2. Oth |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 1-11083 BOSTON SCIENTIFIC CORPORATION (Exact name |
|
| May 1, 2024 |
Exhibit 10.1 Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan Global Non-Qualified Stock Option Agreement This Global Non-Qualified Stock Option Agreement (the “Agreement”), is between you and Boston Scientific Corporation, a Delaware corporation, (the “Company”) in connection with the Non-Qualified Stock Option Award granted to you by the Committee under the Boston |
|
| May 1, 2024 |
Exhibit 10.3 Boston Scientific Corporation Participant: %%FIRSTNAME%-% %%LASTNAME%-% Employee ID: %%EMPLOYEEIDENTIFIER%-% Award Type: Performance Share Unit Award Agreement Plan Name: rTSR PERFORMANCE SHARE PROGRAM - Award Date: %%OPTIONDATE,'Month DD, YYYY'%-% Total Granted: %%TOTALSHARESGRANTED%-% BOSTON SCIENTIFIC INTENT TO GRANT PERFORMANCE SHARE UNIT AWARD AGREEMENT This Agreement, dated as o |
|
| May 1, 2024 |
Exhibit 10.2 EMPLOYEE COPY PLEASE RETAIN FOR YOUR RECORDS Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan Global Restricted Stock Unit Award Agreement This Global Restricted Stock Unit Award Agreement (the “Agreement”) is between you and Boston Scientific Corporation, a Delaware corporation, (the “Company”) in connection with the award of Restricted Stock Units (th |
|
| May 1, 2024 |
Exhibit 10.4 Boston Scientific Corporation Participant: %%FIRSTNAME%-% %%LASTNAME%-% Employee ID: %%EMPLOYEEIDENTIFIER%-% Award Type: Performance Share Unit Award Agreement Plan Name: ONSG PERFORMANCE SHARE PROGRAM Award Date: %%OPTIONDATE,'Month DD, YYYY'%-% Total Granted: %%TOTALSHARESGRANTED%-% BOSTON SCIENTIFIC INTENT TO GRANT PERFORMANCE SHARE UNIT AWARD AGREEMENT This Agreement, dated as of |
|
| May 1, 2024 |
EXHIBIT 22 Subsidiary Issuer of Guaranteed Securities Boston Scientific (the “Registrant”) is the guarantor of the senior unsecured registered notes listed below issued by American Medical Systems Europe B. |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| April 24, 2024 |
Boston Scientific Announces Results for First Quarter 2024 Boston Scientific Announces Results for First Quarter 2024 Marlborough, Mass. (April 24, 2024) - Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent on a reported basis, 15.0 percent on an operational1 basis and 13.1 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net i |
|
| April 24, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 24, 2024 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I. |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 3, 2024 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commissi |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confide |
|
| February 27, 2024 |
Boston Scientific Announces Pricing of €2.0 Billion of Senior Notes Exhibit 99.1 Boston Scientific Announces Pricing of €2.0 Billion of Senior Notes MARLBOROUGH, Mass., February 22, 2024 – Boston Scientific Corporation (the “Company”) (NYSE: BSX) today announced that American Medical Systems Europe B.V., its wholly owned finance subsidiary, has priced a public offering of €750,000,000 aggregate principal amount of 3.375% notes due 2029 and €1,250,000,000 aggregate |
|
| February 27, 2024 |
Exhibit 1.1 EXECUTION VERSION AMERICAN MEDICAL SYSTEMS EUROPE B.V., as Issuer Debt Securities Fully and Unconditionally Guaranteed by BOSTON SCIENTIFIC CORPORATION UNDERWRITING AGREEMENT-BASIC PROVISIONS February 22, 2024 To: The Underwriters named in the within-mentioned Terms Agreement Ladies and Gentlemen: American Medical Systems Europe B.V. (the “Issuer”), incorporated as a private company wi |
|
| February 27, 2024 |
Boston Scientific Announces Completion of €2.0 Billion Offering of Senior Notes Exhibit 99.2 Boston Scientific Announces Completion of €2.0 Billion Offering of Senior Notes MARLBOROUGH, Mass., February 27, 2024 – Boston Scientific Corporation (NYSE: BSX) (the “Company”) today announced that American Medical Systems Europe B.V., its wholly owned finance subsidiary, has completed a public offering of €750,000,000 aggregate principal amount of 3.375% notes due 2029 and €1,250,00 |
|
| February 27, 2024 |
Form of 3.375% Senior Note due 2029. Exhibit 4.2 THIS GLOBAL SECURITY IS REGISTERED IN THE NAME OF THE ENTITY APPOINTED AS COMMON DEPOSITARY (AS DEFINED IN THE INDENTURE) OR A NOMINEE OF THE COMMON DEPOSITARY. THIS GLOBAL SECURITY IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE COMMON DEPOSITARY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND NO TRANSFER OF THIS |
|
| February 27, 2024 |
Form of 3.500% Senior Note due 2032. Exhibit 4.3 THIS GLOBAL SECURITY IS REGISTERED IN THE NAME OF THE ENTITY APPOINTED AS COMMON DEPOSITARY (AS DEFINED IN THE INDENTURE) OR A NOMINEE OF THE COMMON DEPOSITARY. THIS GLOBAL SECURITY IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE COMMON DEPOSITARY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND NO TRANSFER OF THIS |
|
| February 27, 2024 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 22, 2024 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Comm |
|
| February 23, 2024 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(2) Registration No. 333-262937 PROSPECTUS SUPPLEMENT (To Prospectus dated February 23, 2022) €2,000,000,000 American Medical Systems Europe B.V. (incorporated as a private company with limited liability in the Netherlands with its statutory seat in Amsterdam, the Netherlands) €750,000,000 3.375% Senior Notes due 2029 €1,250,000,000 3.500% Senior No |
|
| February 23, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(2) (Form Type) Boston Scientific Corporation (Exact Name of Registrant as Specified in its Charter) American Medical Systems Europe B. |
|
| February 22, 2024 |
Filed Pursuant to Rule 433 under the Securities Act of 1933 Registration Statement No. |
|
| February 22, 2024 |
SUBJECT TO COMPLETION, DATED FEBRUARY 22, 2024 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934, or For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 1-11083 BOSTON SCIENTIFIC CORPORATION (Exact name of |
|
| February 20, 2024 |
Boston Scientific Corporation Dodd-Frank Clawback Policy Exhibit 97 BOSTON SCIENTIFIC CORPORATION DODD-FRANK CLAWBACK POLICY Purpose: The purpose of this policy is to comply with applicable provisions of The New York Stock Exchange Listed Company Manual, promulgated pursuant to the final rules adopted by the Securities and Exchange Commission enacting the clawback standards under Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act, with respect to the recoupment of incentive-based compensation. |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934, or For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 1-11083 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as speci |
|
| February 20, 2024 |
Exhibit 10.30 THE BOSTON SCIENTIFIC CORPORATION EXECUTIVE RETIREMENT PLAN As Amended and Restated Effective June 1, 2022 Section 1—Nature and Purpose Boston Scientific Corporation maintains the Boston Scientific Corporation Executive Retirement Plan, which is an unfunded, nonqualified deferred compensation plan for a select group of management and highly compensated employees. The Plan is intended |
|
| February 20, 2024 |
List of Boston Scientific's subsidiaries as of January 31, 2024. EXHIBIT 21 List of worldwide subsidiaries of Boston Scientific Corporation as of January 31, 2024 Structure of ownership and control: Boston Scientific wholly owns or has a majority interest in all of the below mentioned entities. |
|
| February 13, 2024 |
BSX / Boston Scientific Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0462-bostonscientificcorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Boston Scientific Corp Title of Class of Securities: Common Stock CUSIP Number: 101137107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to |
|
| February 9, 2024 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* BOSTON SCIENTIFIC CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 101137107 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 26, 2024 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commi |
|
| January 31, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 31, 2024 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I. |
|
| January 31, 2024 |
Boston Scientific Announces Results for Fourth Quarter and Full Year 2023 FOR IMMEDIATE RELEASE Boston Scientific Announces Results for Fourth Quarter and Full Year 2023 Marlborough, Mass. |
|
| January 8, 2024 |
Exhibit 99.1 Boston Scientific Announces Agreement to Acquire Axonics, Inc. Acquisition to expand urology portfolio with differentiated technologies to treat urinary and bowel dysfunction MARLBOROUGH, Mass., Jan. 8, 2024 – Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Axonics, Inc. (Nasdaq: AXNX), a publicly traded medical technolog |
|
| January 8, 2024 |
investorpresentationdate Boston Scientific Acquisition of Axonics, Inc. January 8, 2024 Exhibit 99.2 2 Certain statements that we may make from time to time, including statements contained in this presentation and information incorporated by reference herein, constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exch |
|
| January 8, 2024 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among BOSTON SCIENTIFIC CORPORATION, SADIE MERGER SUB, INC. and AXONICS, INC. Dated as of January 8, 2024 TABLE OF CONTENTS Page ARTICLE I THE MERGER SECTION 1.01 The Merger 2 SECTION 1.02 Closing 2 SECTION 1.03 Effective Time 2 SECTION 1.04 Effects of the Merger 2 SECTION 1.05 Certificate of Incorporation and Bylaws of the Surviving Corporation 2 SECTION 1 |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 8, 2024 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commis |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 8, 2024 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commis |
|
| November 22, 2023 |
Boston Scientific Corporation 2024 Annual Bonus Plan, effective as of January 1, 2024 Exhibit 10.1 2024 Boston Scientific Annual Bonus Plan Performance Period January 1 - December 31 Version: November 2023 I.Establishment and Purpose of the Plan Boston Scientific Corporation has established the Boston Scientific Corporation Annual Bonus Plan ("Plan"). As explained in detail below, the Plan basically works as follows. For each Performance Year, there is an Aggregate Bonus Pool, whic |
|
| November 22, 2023 |
Exhibit 10.3 Boston Scientific Corporation (“Boston Scientific”) Organic Net Sales Growth Performance Share Program (“ONSG Program”) Performance Period January 1, 2024 - December 31, 2026 I.Purpose of the ONSG Program The purpose of the ONSG Program is to align Boston Scientific’s executive compensation program with the interests of shareholders and to reinforce the concept of pay for performance |
|
| November 22, 2023 |
Exhibit 10.2 Boston Scientific Corporation (“Boston Scientific”) Relative Total Shareholder Return Performance Share Program (“rTSR Program”) Performance Period January 1, 2024 - December 31, 2026 I.Purpose of the rTSR Program The purpose of the rTSR Program is to align Boston Scientific’s executive compensation program with the interests of shareholders and to reinforce the concept of pay for per |
|
| November 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 16, 2023 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Comm |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 1-11083 BOSTON SCIENTIFIC CORPORATION (Exact n |
|
| October 26, 2023 |
BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR THIRD QUARTER 2023 FOR IMMEDIATE RELEASE BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR THIRD QUARTER 2023 Marlborough, Mass. |
|
| October 26, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 26, 2023 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I. |
|
| August 3, 2023 |
Certificate of Elimination relating to the 5.50% Mandatory Convertible Preferred Stock, Series A. Exhibit 3.1 CERTIFICATE OF ELIMINATION OF 5.50% MANDATORY CONVERTIBLE PREFERRED STOCK, SERIES A OF BOSTON SCIENTIFIC CORPORATION Boston Scientific Corporation, a Delaware corporation (the “Corporation”), hereby certifies that, pursuant to the provisions of Sections 103, 141 and 151 of the General Corporation Law of the State of Delaware: 1.On May 19, 2020, the board of directors of the Corporation |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 1-11083 BOSTON SCIENTIFIC CORPORATION (Exact name o |
|
| July 27, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 27, 2023 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I. |
|
| July 27, 2023 |
BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR SECOND QUARTER 2023 FOR IMMEDIATE RELEASE BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR SECOND QUARTER 2023 Marlborough, Mass. |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 27, 2023 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commissi |
|
| June 27, 2023 |
Press Release issued by Boston Scientific Corporation, dated June 27, 2023. FOR IMMEDIATE RELEASE Boston Scientific Elects Dr. Jessica L. Mega and Susan E. Morano to Board of Directors MARLBOROUGH, Mass., (June 27, 2023) – Boston Scientific Corporation (NYSE: BSX) announced today the election of Dr. Jessica L. Mega and Susan E. Morano to its board of directors, each effective immediately. Dr. Mega is the co-founder of Verily Life Sciences LLC, a subsidiary of Alphabet Inc |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One): þ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 1, 2023 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commissio |
|
| June 1, 2023 |
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on June 12, 2023, pursuant to the provisions of Rule 12d2-2 (a). |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM SD Specialized Disclosure Report BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) DELAWARE 1-11083 04-2695240 (State or other (Commission (IRS employer jurisdiction of file number) identification no. |
|
| May 25, 2023 |
Exhibit 1.01 — Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. Exhibit 1.01 Conflict Minerals Report of Boston Scientific Corporation For the Year Ended December 31, 2022 This Conflict Minerals Report (this “Report”) of Boston Scientific Corporation for the year ended December 31, 2022 is filed in accordance with the rules under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Rule 13p-1 under the Exchange Act (the “Rule”) imposes certain |
|
| May 9, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 4, 2023 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commission |
|
| May 4, 2023 |
Exhibit 10.5 Boston Scientific Corporation Participant: %%FIRSTNAME%-% %%LASTNAME%-% Employee ID: %%EMPLOYEEIDENTIFIER%-% Award Type: Performance Share Unit Award Agreement Plan Name: ONSG PERFORMANCE SHARE PROGRAM Award Date: %%OPTIONDATE,'Month DD, YYYY'%-% Total Granted: %%TOTALSHARESGRANTED%-% BOSTON SCIENTIFIC INTENT TO GRANT PERFORMANCE SHARE UNIT AWARD AGREEMENT This Agreement, dated as of |
|
| May 4, 2023 |
EXHIBIT 22 Subsidiary Issuer of Guaranteed Securities Boston Scientific (the “Registrant”) is the guarantor of the senior unsecured registered notes listed below issued by American Medical Systems Europe B. |
|
| May 4, 2023 |
Exhibit 10.2 Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan Global Non-Qualified Stock Option Agreement This Global Non-Qualified Stock Option Agreement (the “Agreement”), is between you and Boston Scientific Corporation, a Delaware corporation, (the “Company”) in connection with the Non-Qualified Stock Option Award granted to you by the Committee under the Boston |
|
| May 4, 2023 |
Exhibit 10.4 Boston Scientific Corporation Participant: %%FIRSTNAME%-% %%LASTNAME%-% Employee ID: %%EMPLOYEEIDENTIFIER%-% Award Type: Performance Share Unit Award Agreement Plan Name: rTSR PERFORMANCE SHARE PROGRAM - Award Date: %%OPTIONDATE,'Month DD, YYYY'%-% Total Granted: %%TOTALSHARESGRANTED%-% BOSTON SCIENTIFIC INTENT TO GRANT PERFORMANCE SHARE UNIT AWARD AGREEMENT This Agreement, dated as o |
|
| May 4, 2023 |
Exhibit 10.3 Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan Global Restricted Stock Unit Award Agreement This Global Restricted Stock Unit Award Agreement (the “Agreement”) is between you and Boston Scientific Corporation, a Delaware corporation, (the “Company”) in connection with the award of Restricted Stock Units (the “Award”) by the Committee under the Boston |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 1-11083 BOSTON SCIENTIFIC CORPORATION (Exact name |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 26, 2023 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I. |
|
| April 26, 2023 |
BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FIRST QUARTER 2023 FOR IMMEDIATE RELEASE BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FIRST QUARTER 2023 Marlborough, Mass. |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confid |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Comm |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| March 1, 2023 |
Exhibit 10.1 EXECUTION VERSION SECOND AMENDMENT SECOND AMENDMENT, dated as of March 1, 2023 (this “Amendment”), to the Credit Agreement, dated as of May 10, 2021 (as amended by that certain Amendment dated as of December 21, 2022, and as further amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), among (i) BOSTON SCIENTIFIC CORPORATION, a Delaware corporation (t |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 1, 2023 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commissi |
|
| February 23, 2023 |
Exhibit 10.72 Execution Version AMENDMENT AMENDMENT, dated as of December 21, 2022 (this “Amendment”), to the Credit Agreement, dated as of May 10, 2021 (as amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), among (i) BOSTON SCIENTIFIC CORPORATION, a Delaware corporation (the “Borrower”), (ii) the several banks and other financial institutions from time to time |
|
| February 23, 2023 |
Exhibit 10.58 BOSTON SCIENTIFIC CORPORATION DEFERRED STOCK UNIT AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORS This Agreement, dated as of the %%OPTIONDATE,’Month DD, YYYY%-% (the “Grant Date”), is between Boston Scientific Corporation, a Delaware corporation (the “Company”), and the person whose name appears on the Signature Page of this Agreement (the “Participant”), a non-employee director of the C |
|
| February 23, 2023 |
Exhibit 10.79 Boston Scientific Corporation Participant: %%FIRSTNAME%-% %%LASTNAME%-% Employee ID: %%EMPLOYEEIDENTIFIER%-% Award Type: Performance Share Unit Award Agreement Plan Name: FCF PERFORMANCE SHARE PROGRAM Award Date: %%OPTIONDATE,’Month DD, YYYY’%-% Total Granted: %%TOTALSHARESGRANTED%-% BOSTON SCIENTIFIC INTENT TO GRANT PERFORMANCE SHARE UNIT AWARD AGREEMENT This Agreement, dated as of |
|
| February 23, 2023 |
Exhibit 10.84 One Boston Scientific Place Natick, MA 01760-1537 508.650.8000 December 11, 2012 Mr. Jeffrey Mirviss ADDRESS LINE ADDRESS LINE Dear Jeff: Based on your role within Boston Scientific, we are very pleased to offer you the position of Senior Vice President and President, Peripheral Interventions reporting to Michael Mahoney, President and Chief Executive Officer, effective January 1, 20 |
|
| February 23, 2023 |
Exhibit 10.70 BOSTON SCIENTIFIC CORPORATION RESTRICTED STOCK UNIT AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORS This Agreement, dated as of the %%OPTIONDATE,’Month DD, YYYY%-% (the “Grant Date”), is between Boston Scientific Corporation, a Delaware corporation (the “Company”), and the person whose name appears on the Signature Page of this Agreement (the “Participant”), a non-employee director of the |
|
| February 23, 2023 |
Exhibit 10.76 Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan Global Non-Qualified Stock Option Agreement This Global Non-Qualified Stock Option Agreement (the “Agreement”), is between you and Boston Scientific Corporation, a Delaware corporation, (the “Company”) in connection with the Non-Qualified Stock Option Award granted to you by the Committee under the Bosto |
|
| February 23, 2023 |
Exhibit 10.66 EMPLOYEE COPY PLEASE RETAIN FOR YOUR RECORDS Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan Global Restricted Stock Unit Award Agreement This Global Restricted Stock Unit Award Agreement (the “Agreement”) is between you and Boston Scientific Corporation, a Delaware corporation, (the “Company”) in connection with the award of Restricted Stock Units (t |
|
| February 23, 2023 |
Exhibit 10.77 Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan Global Restricted Stock Unit Award Agreement This Global Restricted Stock Unit Award Agreement (the “Agreement”) is between you and Boston Scientific Corporation, a Delaware corporation, (the “Company”) in connection with the award of Restricted Stock Units (the “Award”) by the Committee under the Boston |
|
| February 23, 2023 |
Exhibit 10.67 Boston Scientific Corporation Participant: %%FIRSTNAME%-% %%LASTNAME%-% Employee ID: %%EMPLOYEEIDENTIFIER%-% Award Type: Performance Share Unit Award Agreement Plan Name: TSR PERFORMANCE SHARE PROGRAM - Award Date: %%OPTIONDATE,'Month DD, YYYY'%-% Total Granted: %%TOTALSHARESGRANTED%-% BOSTON SCIENTIFIC INTENT TO GRANT PERFORMANCE SHARE UNIT AWARD AGREEMENT This Agreement, dated as o |
|
| February 23, 2023 |
List of Boston Scientific's subsidiaries as of January 31, 202 EXHIBIT 21 List of worldwide subsidiaries of Boston Scientific Corporation as of January 31, 2023 Structure of ownership and control: Boston Scientific wholly owns or has a majority interest in all of the below mentioned entities. |
|
| February 23, 2023 |
Exhibit 10.65 Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan Global Non-Qualified Stock Option Agreement This Global Non-Qualified Stock Option Agreement (the “Agreement”), is between you and Boston Scientific Corporation, a Delaware corporation, (the “Company”) in connection with the Non-Qualified Stock Option Award granted to you by the Committee under the Bosto |
|
| February 23, 2023 |
Exhibit 10.56 Boston Scientific Corporation 2011 Long-Term Incentive Plan Global Deferred Stock Unit Award Agreement %%OPTIONDATE,’Month DD, YYYY’%-% %%FIRSTNAME%-% %%LASTNAME%-% (“Participant”) EMPLOYEE COPY PLEASE RETAIN FOR YOUR RECORDS Boston Scientific Corporation 2011 Long-Term Incentive Plan Global Deferred Stock Unit Award Agreement This Global Deferred Stock Unit Award Agreement (the “Agr |
|
| February 23, 2023 |
Exhibit 10.55 Boston Scientific Corporation 2011 Long-Term Incentive Plan Global Non-Qualified Stock Option Agreement %%OPTIONDATE,’Month DD, YYYY’%-% %%FIRSTNAME%-% %%LASTNAME%-% (“Optionee”) EMPLOYEE COPY PLEASE RETAIN FOR YOUR RECORDS Boston Scientific Corporation 2011 Long-Term Incentive Plan Global Non-Qualified Stock Option Agreement This Global Non-Qualified Stock Option Agreement (the “Agr |
|
| February 23, 2023 |
Exhibit 10.57 BOSTON SCIENTIFIC CORPORATION RESTRICTED STOCK AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORS This Agreement, dated as of the %%OPTIONDATE,’Month DD, YYYY%-% (the “Grant Date”), is between Boston Scientific Corporation, a Delaware corporation (the “Company”), and the person whose name appears on the Signature Page of this Agreement (the “Participant”), a non-employee director of the Comp |
|
| February 23, 2023 |
Exhibit 10.80 BOSTON SCIENTIFIC CORPORATION RESTRICTED STOCK AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORS This Agreement, dated as of the %%OPTIONDATE,’Month DD, YYYY%-% (the “Grant Date”), is between Boston Scientific Corporation, a Delaware corporation (the “Company”), and the person whose name appears on the Signature Page of this Agreement (the “Participant”), a non-employee director of the Comp |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934, or For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 1-11083 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as speci |
|
| February 23, 2023 |
Exhibit 10.81 BOSTON SCIENTIFIC CORPORATION RESTRICTED STOCK UNIT AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORS This Agreement, dated as of the %%OPTIONDATE,’Month DD, YYYY%-% (the “Grant Date”), is between Boston Scientific Corporation, a Delaware corporation (the “Company”), and the person whose name appears on the Signature Page of this Agreement (the “Participant”), a non-employee director of the |
|
| February 23, 2023 |
Exhibit 10.83 April 1, 2022 Arthur Butcher ADDRESS LINE ADDRESS LINE Dear Art: Congratulations on your promotion to Executive Vice President and Group President, Medsurg and APAC effective May 2, 2022. You will continue to be a member of Boston Scientific’s Executive Committee, an “executive officer” under the U.S. federal securities laws and an “officer” for purposes of Section 16 of the Exchange |
|
| February 23, 2023 |
EXHIBIT 10.85 BOSTON SCIENTIFIC CORPORATION NON-EMPLOYEE DIRECTOR DEFERRED COMPENSATION PLAN As Amended and Restated Effective January 1, 2023 BOSTON SCIENTIFIC CORPORATION NON-EMPLOYEE DIRECTOR DEFERRED COMPENSATION PLAN As Amended and Restated Effective January 1, 2023 Table of Contents Page Article 1 Nature and Purpose of Plan 1 1.1 Nature 1 1.2 Purpose 1 Article 2 Participation 1 2.1 Commencem |
|
| February 23, 2023 |
Exhibit 10.68 Boston Scientific Corporation Participant: %%FIRSTNAME%-% %%LASTNAME%-% Employee ID: %%EMPLOYEEIDENTIFIER%-% Award Type: Performance Share Unit Award Agreement Plan Name: FCF PERFORMANCE SHARE PROGRAM Award Date: %%OPTIONDATE,'Month DD, YYYY'%-% Total Granted: %%TOTALSHARESGRANTED%-% BOSTON SCIENTIFIC INTENT TO GRANT PERFORMANCE SHARE UNIT AWARD AGREEMENT This Agreement, dated as of |
|
| February 23, 2023 |
EX-10.78 15 ex1078-2022grantxtsragreem.htm EX-10.78 Exhibit 10.78 Boston Scientific Corporation Participant: %%FIRSTNAME%-% %%LASTNAME%-% Employee ID: %%EMPLOYEEIDENTIFIER%-% Award Type: Performance Share Unit Award Agreement Plan Name: TSR PERFORMANCE SHARE PROGRAM - Award Date: %%OPTIONDATE,’Month DD, YYYY’%-% Total Granted: %%TOTALSHARESGRANTED%-% BOSTON SCIENTIFIC INTENT TO GRANT PERFORMANCE S |
|
| February 23, 2023 |
Exhibit 10.69 BOSTON SCIENTIFIC CORPORATION RESTRICTED STOCK AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORS This Agreement, dated as of the %%OPTIONDATE,’Month DD, YYYY%-% (the “Grant Date”), is between Boston Scientific Corporation, a Delaware corporation (the “Company”), and the person whose name appears on the Signature Page of this Agreement (the “Participant”), a non-employee director of the Comp |
|
| February 9, 2023 |
BSX / Boston Scientific Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0442-bostonscientificcorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Boston Scientific Corp. Title of Class of Securities: Common Stock CUSIP Number: 101137107 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* BOSTON SCIENTIFIC CORP (Name of Issuer) Common Stock (Title of Class of Securities) 101137107 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Boston Scientific Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 101137107 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| February 1, 2023 |
BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2022 FOR IMMEDIATE RELEASE BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2022 Marlborough, Mass. |
|
| February 1, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 1, 2023 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I. |
|
| January 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 31, 2023 (January 29, 2023) BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commission file number) (IRS employer identification no. |
|
| November 21, 2022 |
EX-10.2 3 exhibit102bostonscientific.htm EX-10.2 Boston Scientific Corporation (“Boston Scientific”) Relative Total Shareholder Return Performance Share Program (“rTSR Program”) Performance Period January 1, 2023 - December 31, 2025 I.Purpose of the rTSR Program The purpose of the rTSR Program is to align Boston Scientific’s executive compensation program with the interests of shareholders and to |
|
| November 21, 2022 |
Boston Scientific Corporation (?Boston Scientific?) Organic Net Sales Growth Performance Share Program (?ONSG Program?) Performance Period January 1, 2023 - December 31, 2025 I. |
|
| November 21, 2022 |
Boston Scientific Corporation 2023 Annual Bonus Plan, effective as of January 1, 2023 2023 Boston Scientific Annual Bonus Plan Performance Period January 1 - December 31 Version: November 2022 I. |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): (November 21, 2022) November 18, 2022 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of |
|
| November 3, 2022 |
Subsidiary Issuer of Guaranteed Securities EXHIBIT 22 Subsidiary Issuer of Guaranteed Securities Boston Scientific (the ?Registrant?) is the guarantor of the senior unsecured registered notes listed below issued by American Medical Systems Europe B. |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 1-11083 BOSTON SCIENTIFIC CORPORATION (Exact n |
|
| October 26, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 26, 2022 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I. |
|
| October 26, 2022 |
Boston Scientific Announces Results for Third Quarter 2022 FOR IMMEDIATE RELEASE Boston Scientific Announces Results for Third Quarter 2022 Marlborough, Mass. |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 1-11083 BOSTON SCIENTIFIC CORPORATION (Exact name o |
|
| August 4, 2022 |
Subsidiary Issuer of Guaranteed Securities EXHIBIT 22 Subsidiary Issuer of Guaranteed Securities Boston Scientific (the ?Registrant?) is the guarantor of the senior unsecured registered notes listed below issued by American Medical Systems Europe B. |
|
| July 27, 2022 |
Boston Scientific Announces Results for Second Quarter 2022 FOR IMMEDIATE RELEASE Boston Scientific Announces Results for Second Quarter 2022 Marlborough, Mass. |
|
| July 27, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 27, 2022 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I. |
|
| June 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One): þ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION |
|
| May 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM SD Specialized Disclosure Report BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) DELAWARE 1-11083 04-2695240 (State or other (Commission (IRS employer jurisdiction of file number) identification no. |
|
| May 25, 2022 |
Exhibit 1.01 — Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. Exhibit 1.01 Conflict Minerals Report of Boston Scientific Corporation For the Year Ended December 31, 2021 This Conflict Minerals Report (this ?Report?) of Boston Scientific Corporation for the year ended December 31, 2021 is filed in accordance with the rules under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). Rule 13p-1 under the Exchange Act (the ?Rule?) imposes certain |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 6, 2022 (May 3, 2022) BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commission file number) (IRS employer identification no. |
|
| May 6, 2022 |
Exhibit 10.2 BOSTON SCIENTIFIC CORPORATION EMPLOYEE STOCK PURCHASE PLAN Amended and Restated Effective as of July 1, 2022 1. Purpose. The purpose of the Boston Scientific Corporation Employee Stock Purchase Plan, as amended and renamed (formerly known as the Boston Scientific Corporation 2006 Global Employee Stock Ownership Plan), is to encourage ownership of common stock by employees of Boston Sc |
|
| May 6, 2022 |
As filed with the Securities and Exchange Commission on May 6, 2022 As filed with the Securities and Exchange Commission on May 6, 2022 Registration No. |
|
| May 6, 2022 |
Exhibit 10.1 [FORM OF EC NON-CEO CHANGE IN CONTROL AGREEMENT] [INSERT NAME] [INSERT ADDRESS] Re: Change in Control Agreement Dear [INSERT FIRST NAME]: Boston Scientific Corporation (the ?Company?) considers it essential to the best interests of its stockholders to foster the continuous employment of key management personnel. Further, the Board of Directors of the Company (the ?Board?) recognizes t |
|
| May 6, 2022 |
Exhibit 107 Form S-8 Boston Scientific Corporation CALCULATION OF REGISTRATION FEE Table 1 - Newly Registered Securities Security Type Security Class Type Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 1-11083 BOSTON SCIENTIFIC CORPORATION (Exact name |
|
| May 5, 2022 |
Subsidiary Issuer of Guaranteed Securities EXHIBIT 22 Subsidiary Issuer of Guaranteed Securities Boston Scientific (the ?Registrant?) is the guarantor of the senior unsecured registered notes listed below issued by American Medical Systems Europe B. |
|
| April 27, 2022 |
BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FIRST QUARTER 2022 FOR IMMEDIATE RELEASE BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FIRST QUARTER 2022 Marlborough, Mass. |
|
| April 27, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 27, 2022 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I. |
|
| April 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 5, 2022 (March 30, 2022) BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorpo |
|
| March 23, 2022 |
DEFA14A 1 tm223423d4defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate bo |
|
| March 23, 2022 |
DEF 14A 1 tm223423d3def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box |
|
| March 17, 2022 |
Exhibit 99.1 Boston Scientific Announces Early Results of Its Cash Tender Offer for Its Outstanding Debt Securities and Increases Aggregate Maximum Principal Amount of Its Cash Tender Offer MARLBOROUGH, Mass., March 16, 2022 /PRNewswire/ - Boston Scientific Corporation (the ?Company?) (NYSE:BSX) today announced that, pursuant to the previously announced cash tender offer (the ?Tender Offer?) for u |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 17, 2022 (March 16, 2022) BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorp |
|
| March 17, 2022 |
Boston Scientific Announces Pricing Terms of Its Cash Tender Offer Exhibit 99.2 Boston Scientific Announces Pricing Terms of Its Cash Tender Offer MARLBOROUGH, Mass., March 16, 2022 /PRNewswire/ - Boston Scientific Corporation (the ?Company?) (NYSE:BSX) today announced the pricing terms of the previously announced upsized cash tender offer (the ?Tender Offer?) for $2,852,561,000 in aggregate principal amount (the ?Aggregate Maximum Principal Amount?) of the outst |
|
| March 8, 2022 |
Form of 1.875% Senior Note due 2034. Exhibit 4.5 THIS GLOBAL SECURITY IS REGISTERED IN THE NAME OF THE ENTITY APPOINTED AS COMMON SAFEKEEPER (AS DEFINED IN THE INDENTURE) OR A NOMINEE OF THE COMMON SAFEKEEPER. THIS GLOBAL SECURITY IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE COMMON SAFEKEEPER OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND NO TRANSFER OF THIS |
|
| March 8, 2022 |
Exhibit 1.1 EXECUTION VERSION American Medical Systems Europe B.V., as Issuer Debt Securities Fully and Unconditionally Guaranteed by BOSTON SCIENTIFIC CORPORATION UNDERWRITING AGREEMENT-BASIC PROVISIONS March 3, 2022 To:??????????The Underwriters named in the within-mentioned Terms Agreement Ladies and Gentlemen: American Medical Systems Europe B.V. (the ?Issuer?), incorporated as a private compa |
|
| March 8, 2022 |
Exhibit 4.1 Execution Version BOSTON SCIENTIFIC CORPORATION AND American Medical Systems Europe B.V., as Issuer or Guarantor, as applicable, for each series of Securities from time to time AND U.S. Bank Trust Company, National Association, as Trustee Indenture Dated as of March 8, 2022 DEBT SECURITIES BOSTON SCIENTIFIC CORPORATION American Medical Systems Europe B.V. Reconciliation and tie between |
|
| March 8, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 8, 2022 (March 3, 2022) BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorpor |
|
| March 8, 2022 |
Form of 1.625% Senior Note due 2031. Exhibit 4.4 THIS GLOBAL SECURITY IS REGISTERED IN THE NAME OF THE ENTITY APPOINTED AS COMMON SAFEKEEPER (AS DEFINED IN THE INDENTURE) OR A NOMINEE OF THE COMMON SAFEKEEPER. THIS GLOBAL SECURITY IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE COMMON SAFEKEEPER OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND NO TRANSFER OF THIS |
|
| March 8, 2022 |
Form of 1.375% Senior Note due 2028. Exhibit 4.3 THIS GLOBAL SECURITY IS REGISTERED IN THE NAME OF THE ENTITY APPOINTED AS COMMON SAFEKEEPER (AS DEFINED IN THE INDENTURE) OR A NOMINEE OF THE COMMON SAFEKEEPER. THIS GLOBAL SECURITY IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE COMMON SAFEKEEPER OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND NO TRANSFER OF THIS |
|
| March 8, 2022 |
Form of 0.750% Senior Note due 2025. Exhibit 4.2 THIS GLOBAL SECURITY IS REGISTERED IN THE NAME OF THE ENTITY APPOINTED AS COMMON SAFEKEEPER (AS DEFINED IN THE INDENTURE) OR A NOMINEE OF THE COMMON SAFEKEEPER. THIS GLOBAL SECURITY IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE COMMON SAFEKEEPER OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND NO TRANSFER OF THIS |
|
| March 8, 2022 |
Boston Scientific Announces Completion of €3.0 Billion Offering of Senior Notes Exhibit 99.2 Boston Scientific Announces Completion of ?3.0 Billion Offering of Senior Notes MARLBOROUGH, Mass., March 8, 2022 /PRNewswire/ - Boston Scientific Corporation (NYSE: BSX) (the ?Company?) today announced that American Medical Systems Europe B.V., its wholly owned finance subsidiary, has completed a public offering of ?1,000,000,000 aggregate principal amount of 0.750% notes due 2025, ? |
|
| March 8, 2022 |
Boston Scientific Announces Pricing of €3.0 Billion of Senior Notes Exhibit 99.1 Boston Scientific Announces Pricing of ?3.0 Billion of Senior Notes MARLBOROUGH, Mass., March 3, 2022 /PRNewswire/ - Boston Scientific Corporation (the ?Company?) (NYSE: BSX) today announced that American Medical Systems Europe B.V., its wholly owned finance subsidiary, has priced a public offering of ?1,000,000,000 aggregate principal amount of 0.750% notes due 2025, ?750,000,000 agg |
|
| March 4, 2022 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(2) (Form Type) Boston Scientific Corporation (Exact Name of Registrant as Specified in its Charter) American Medical Systems Europe B. |
|
| March 4, 2022 |
TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(2)? ?Registration No. 333-262937? PROSPECTUS SUPPLEMENT (To Prospectus dated February 23, 2022) ?3,000,000,000 American Medical Systems Europe B.V. (incorporated as a private company with limited liability in the Netherlands with its statutory seat in Amsterdam, the Netherlands) ?1,000,000,000 0.750% Senior Notes due 2025 ?750,000,000 1.375% Senior |
|
| March 3, 2022 |
SUBJECT TO COMPLETION, DATED MARCH 3, 2022 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| March 3, 2022 |
Filed Pursuant to Rule 433 under the Securities Act of 1933 Registration Statement No. |
|
| March 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 2, 2022 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commissi |
|
| March 2, 2022 |
Exhibit 99.1 Boston Scientific Announces Cash Tender Offer For Up To $2.5 Billion Of Its Outstanding Debt Securities MARLBOROUGH, Mass. (March 2, 2022) ? Boston Scientific Corporation (the ?Company?) (NYSE:BSX) today announced the commencement of a cash tender offer (the ?Tender Offer?) for up to $2.5 billion aggregate principal amount (the ?Aggregate Maximum Principal Amount?) of the outstanding |
|
| February 23, 2022 |
As filed with the Securities and Exchange Commission on February 23, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on February 23, 2022 Registration No. |
|
| February 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934, or For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 1-11083 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as speci |
|
| February 23, 2022 |
DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K of which this exhibit is a part, Boston Scientific Corporation (the ?Company?) has three classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): (1) our common stock, $. |
|
| February 23, 2022 |
and the other Issuers and Guarantors, as applicable, named therein and U.S. Bank Trust Company, Exhibit 4.1 BOSTON SCIENTIFIC CORPORATION American Medical Systems Europe B.V. [ ] as Issuer or Guarantor, as applicable, for each series of Securities from time to time AND U.S. Bank Trust Company, National Association, as Trustee Form of Indenture Dated as of [ ], 20[ ] DEBT SECURITIES BOSTON SCIENTIFIC CORPORATION American Medical Systems Europe B.V. Reconciliation and tie between Trust Indentu |
|
| February 23, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Boston Scientific Corporation (Exact Name of Registrant as Specified in its Charter) American Medical Systems Europe B. |
|
| February 23, 2022 |
EX-25.1 6 tm226870d2ex25-1.htm EXHIBIT 25.1 Exhibit 25.1 securities and exchange commission Washington, D.C. 20549 FORM T-1 Statement of Eligibility Under The Trust Indenture Act of 1939 of a Corporation Designated to Act as Trustee Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) ¨ U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as s |
|
| February 23, 2022 |
Boston Scientific's subsidiaries as of January 31, 202 EXHIBIT 21 List of worldwide subsidiaries of Boston Scientific as of January 31, 2022 Structure of ownership and control: Boston Scientific wholly owns or has a majority interest in all of the below mentioned entities. |
|
| February 15, 2022 |
Boston Scientific Closes Acquisition of Baylis Medical Company Inc. Boston Scientific Closes Acquisition of Baylis Medical Company Inc. MARLBOROUGH, Mass., February 15, 2022? Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Baylis Medical Company Inc., a company that offers advanced transseptal access solutions as well as guidewires, sheaths and dilators used to support catheter-based left-heart procedures. ?The close of th |
|
| February 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 15, 2022 (February 14, 2022) BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I. |
|
| February 10, 2022 |
RNXT / RenovoRx, Inc. / BOSTON SCIENTIFIC CORP - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* RENOVORX, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 75989R107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 9, 2022 |
BSX / Boston Scientific Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Boston Scientific Corp. Title of Class of Securities: Common Stock CUSIP Number: 101137107 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is file |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Boston Scientific Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 101137107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| February 3, 2022 |
LUNG / ProLung, Inc. / BOSTON SCIENTIFIC CORP - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Pulmonx Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 745848101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 2, 2022 |
BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2021 EX-99.1 2 q42021earningsrelease.htm EX-99.1 Q4 2021 EARNINGS RELEASE FOR IMMEDIATE RELEASE BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2021 Marlborough, Mass. (February 2, 2022) - Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.127 billion during the fourth quarter of 2021, growing 15.4 percent on a reported basis, 16.9 percent on an operational1 basis |
|
| February 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BOSTON SCIENTIFIC CORP (Name of Issuer) Common Stock (Title of Class of Securities) 101137107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| February 2, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 2, 2022 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I. |
|
| November 23, 2021 |
2022 Boston Scientific Annual Bonus Plan Performance Period January 1 - December 31 Version: November 2021 I. |
|
| November 23, 2021 |
Boston Scientific Corporation (?Boston Scientific?) Total Shareholder Return Performance Share Program (?TSR Program?) Performance Period January 1, 2022 - December 31, 2024 I. |
|
| November 23, 2021 |
Boston Scientific Corporation (?Boston Scientific?) Free Cash Flow Performance Share Program (?FCF Program?) Performance Period January 1, 2022 - December 31, 2022 I. |
|
| November 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): (November 23, 2021) November 19, 2021 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 9, 2021 (November 8, 2021) BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of in |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 1-11083 BOSTON SCIENTIFIC CORPORATION (Exact n |
|
| October 27, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 27, 2021 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I. |
|
| October 27, 2021 |
October 27, 2021 Notice to Holders of Boston Scientific Corporation?s 7.00% Senior Notes due 2035 (CUSIP No. 101137AE7) Dear Noteholder, Notice is hereby given that the interest rate on Boston Scientific Corporation?s (the ?Company?) $350 million 7.00% Senior Notes due 2035 (the ?2035 Notes?) will be decreased from 7.00% to 6.75% pursuant to Section 201 of the Second Supplemental Indenture, dated |
|
| October 27, 2021 |
BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR THIRD QUARTER 2021 FOR IMMEDIATE RELEASE BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR THIRD QUARTER 2021 Marlborough, Mass. |
|
| October 6, 2021 |
Boston Scientific Announces Agreement to Acquire Baylis Medical Company Inc. Acquisition to add new left heart access platforms to electrophysiology and structural heart portfolios MARLBOROUGH, Mass., October 6, 2021 ? Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Baylis Medical Company Inc. for an upfront payment of $1.75 bill |
|
| October 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 6, 2021 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commis |
|
| September 21, 2021 |
Boston Scientific Announces Agreement to Acquire Devoro Medical, Inc. Company to add mechanical thrombectomy platform to peripheral interventions portfolio MARLBOROUGH, Mass., September 21, 2021 ? Today, Boston Scientific Corporation (NYSE: BSX) announced an agreement to acquire Devoro Medical, Inc., developer of the WOLF Thrombectomy? Platform. The innovative non-console and lytic-free WOLF techn |
|
| September 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 21, 2021 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Com |
|
| September 1, 2021 |
BOSTON SCIENTIFIC CLOSES ACQUISITION OF LUMENIS LTD. SURGICAL BUSINESS FROM BARING PRIVATE EQUITY ASIA MARLBOROUGH, Mass., September 1, 2021? Boston Scientific (NYSE: BSX) today announced the close of its acquisition of the global surgical business of Lumenis LTD., a privately-held company that develops and commercializes energy-based medical solutions, from an affiliate of Baring Private Equity A |
|
| September 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 1, 2021 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Comm |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 1-11083 BOSTON SCIENTIFIC CORPORATION (Exact name o |
